The role of the renin angiotensin hormonal system in the metabolic syndrome and type 2 diabetes

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 14, Issue 2, 2004, Pages 88-93

  Nosadini, R ^a   Tonolo, G ^a  

^a UNIVERSITY OF SASSARI   (Italy)

Author keywords

Renin angiotensin system (RAS); Type 2 diabetes mellitus

Indexed keywords

ALBUMIN; AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INSULIN; LISINOPRIL; LOSARTAN; RAMIPRIL; RENIN; THIAZIDE DIURETIC AGENT;

CLINICAL TRIAL; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG EFFECT; GLUCOSE TOLERANCE; HUMAN; HYPERTENSION; INSULIN SENSITIVITY; KIDNEY INJURY; METABOLIC SYNDROME X; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

EID: 3042681132     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0939-4753(04)80015-2     Document Type: Note

References (19)

1. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) Major outcomes in high-risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 288: 2981-2997
2. Langham R, Kelly D, Cox A, Thomson N, Holthofer H, Zaoui P, Pinel N, Cordonnier D, Gilbert R (2002) Proteinuria and the expression of the podocytes slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition. Diabetologia 45: 1572-1576
3. Boehm M, Nabel E (2202) Angiotensin converting enzyme 2. A new cardiac regulator. N Engl J Med 347: 1795-1797
4. Manolio TA, Cutler JA, Furberg CD, Psaty BM, Whelton PK, Applegate WB (1995) Trends in pharmacologic management of hypertension in the United States. Arch Intern Med 155: 829-837
5. The Diabetes Prevention Program (1999) Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care 22: 623-634
6. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH (1990) Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 335: 827-838, 1990.
7. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, National Heart, Lung, and Blood Institute Joint National Committee on Prevention, detection, evalutation, and Treatment of High Blood Pressure. National High Blood Pressure Education Program Coordinating Committee (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC / report. JAMA 289: 2560-2572
8. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahlof B, de Faire U, Morlin C, Karlberg BE, Wester PO, Bjorck JE (1999) Effect of angiotensin-converting- enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 353: 611-616
9. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G (2000) Effects of angiotensin converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342: 145-153
10. Dahlof B, Devereux RB, Kjeldsen S, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group (2002) Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359: 995-1003
11. Gress T, Nieto J, Shahar E, Wofford M, Brancati F (2000) Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 342: 905-912
12. Appel LJ (2002) The verdict from ALLHAT-Thiazide Diuretics are the preferred initial therapy for hypertension. Editorial. JAMA 288: 3039-3044
13. Guidelines Committeee (2003) 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21: 1011-1053
14. Riordan JR (2003) Angiotensin-I-converting enzyme and its relatives. Genome Biol 4: 225-239
15. Ahima RS, Flier JS (2000) Adipose tissue as an endocrine organ. Trends Endocrinol Metab 11: 327-332
16. Doublier S, Salvidio G, Lupia E, Ruotsalainen V, Verzola D, Deferrari G, Camussi G (2003) Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II. Diabetes 52: 1023-1030
17. Tryggvason K, Wartiovaara J (2001) Molecular basis of glomerular permselectivity. Curr Opin Nephrol Hypertens 10: 543-549
18. Keller G, Zimmer G, Mall G, Ritz E, Ammanu K (2003) Nephron number in patients with primary hypertension. N Engl J Med 348: 101-107
19. Barker DJP, Osmond C, Golding J, Kuh D, Wadsmorth ME (1989) Growth in utero, blood pressure in childhood and adult life, and mortality from cardiovascular diseases. Br Med J 296: 564-567